Some Patients With HER2+ Early Breast Cancer Can Safely Forgo Chemotherapy
Some patients with early HER2-positive breast cancer can safely forgo neoadjuvant chemotherapy, results of the PHERGain trial suggest.
American Society of Clinical Oncology (ASCO)
Tucatinib Plus Trastuzumab Shows Activity in HER2+ Metastatic Biliary Tract Cancer
Treatment with tucatinib and trastuzumab elicits responses in previously treated, HER2-positive metastatic biliary tract cancer.
UCPVax Prompts Immune Responses in MGMT Unmethylated Glioblastoma
UCPVax, an anti-telomerase vaccine, has demonstrated immunogenicity in a phase 2 trial of patients with MGMT unmethylated glioblastoma.
No Benefit Seen With Adjuvant Nivolumab in Gastric/GEJ Cancer
Adding nivolumab to adjuvant chemotherapy did not improve relapse-free survival in a phase 3 trial of patients with gastric/GEJ cancer.
Ribociclib Plus ET Dubbed “New Treatment of Choice” in HR+, HER2- Breast Cancer
Adding ribociclib to standard endocrine therapy improves outcomes in patients with HR+, HER2- early breast cancer, a phase 3 trial suggests.
Obecabtagene Autoleucel Appears Safe, Effective in Relapsed/Refractory B-ALL
Obecabtagene autoleucel produced a high response rate in adults with relapsed/refractory B-ALL in a phase 2 study.
NALIRIFOX Deemed New Reference Regimen for Untreated Metastatic PDAC
NALIRIFOX can improve survival vs gemcitabine plus nab-paclitaxel in patients with previously untreated, metastatic pancreatic ductal adenocarcinoma, a phase 3 trial suggests.
Luspatercept Outperforms ESA in Adults With Lower-Risk MDS
Luspatercept appears more effective than epoetin alfa for treating anemia in patients with ESA-naïve, transfusion-dependent, lower-risk MDS.
Ovarian Ablation/Suppression Linked to Lower Risk of Breast Cancer Recurrence, Death
Ovarian ablation or suppression is associated with a lower risk of recurrence and death in premenopausal women with ER+ breast cancer, a meta-analysis suggests.
Neoadjuvant FOLFIRINOX Does Not Improve OS in Resectable Pancreatic Cancer
Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2023
Loading... 
Loading...